BioSpace News Archive

Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2022.

Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.

LumiraDx Limited announced that it has received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the Company’s common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days.

GeneDx Holdings Corp. announced the closing of its previously announced underwritten public offering of shares of its Class A common stock and concurrent registered direct offering of shares of its Class A common stock.

Dynavax Technologies Corporation announced that effective as of market open today, January 31, 2023, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol “DVAX”.

Edwards Lifesciences reported financial results for the quarter ended December 31, 2022.

Varex Imaging Corporation announced its unaudited financial results for the first quarter of fiscal year 2023.

Prothena Corporation plc (NASDAQ:PRTA) today announced positive topline Phase 1 single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms

Conformal Medical, Inc. announced today the presentation of the one-year data from the company’s initial left atrial appendage occlusion (LAAO) cases with its novel CLAAS® System in patients under conscious sedation without general anesthesia.

Instil Bio, Inc. announced an extension of its previously announced reduction-in-force to a team of approximately 15 employees in the U.S. to lead global business operations, including the consolidation of clinical manufacturing and trial operations of its CoStAR-TIL™ to its active Manchester, U.K. operations.